



November 04, 2021

To whom it may concern

Ferring Pharmaceuticals Co., Ltd.  
Fuji Pharma Co., Ltd.  
Listing: Tokyo Stock Exchange First Section  
Securities code: 4554

### **Expanding access of PROPESS® in Japan through strategic collaboration between Ferring Pharmaceuticals & Fuji Pharma**

Ferring Pharmaceuticals (HQ: Tokyo, Japan, CEO and Representative Director: Rami Suzuki, hereafter "Ferring") and Fuji Pharma Co., Ltd. (HQ: Tokyo, Japan, President: Takayuki Iwai, hereafter "Fuji Pharma") announced today that the companies have agreed to collaborate in Japan for Ferring's innovative product PROPESS® 10mg vaginal delivery system [generic name: Dinoprostone] (hereafter "PROPESS"), which is indicated for cervical ripening. PROPESS provides a convenient alternative to the patients needing labor induction due to its unique retrieval system that enables easy and quick removal at the onset of labor or in the event of complications.

According to the collaboration, from December 1, 2021, Fuji Pharma will be responsible for the sales and distribution of PPROPESS while Ferring remains the Marketing Authorization Holder. PROPESS will be jointly co-promoted by Fuji Pharma and Ferring in Japan which will ensure appropriate access of PROPESS to the patients.

Through this collaboration, Ferring and Fuji Pharma shall continue to strive for maternal-fetal health and safety in Japan.

#### **【Product Outline】**

Brand Name	PROPESS® 10mg vaginal delivery system
Generic Name	Dinoprostone
Approval date in Japan	January 23 <sup>rd</sup> , 2020
Launch date in Japan	April 2 <sup>nd</sup> , 2020
Indications	Initiation of cervical ripening for patients from 37 completed weeks of gestation
Precautions for indications	The condition of the cervix ripening should be diagnosed carefully before PROPESS is applied
Dosage and administration	One PROPESS is administered into the posterior vaginal fornix and the PROPESS is administered for the maximum 12 hours.

For further information, please contact	
<p>Ferring Pharmaceuticals Cp., Ltd. Business Development &amp; Strategy Department</p> <p>TEL : 090-9017-2933 E-mail : <a href="mailto:Minoru.Inabayashi@ferring.com">Minoru.Inabayashi@ferring.com</a></p>	<p>Fuji Pharma Co., Ltd. Corporate Communication Section, Corporate Planning Department</p> <p>TEL : 03-3556-4430 E-mail : <a href="mailto:fsk_ir@fujipharma.jp">fsk_ir@fujipharma.jp</a></p>

### **About PROPESS® 10mg vaginal delivery system**

PROPESS® 10mg vaginal delivery system is the only vaginal inserts for Initiation of cervical ripening for patients from 37 completed weeks of gestation. It is composed of hydrophilic polymer with active ingredients and a containing and retrieval cord, which distributes Dinoprostone continuously by inserting and clinging to cervix as the target site (high into the posterior vaginal fornix).

Since the approval by FDA in 1995, as agent for stimulating cervical ripening, PROPESS® 10mg vaginal delivery system have been approved in more than 70 countries and regions (as of December 2020).

### **About Ferring**

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build healthy families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. Learn more at [www.ferring.com](http://www.ferring.com), or connect with us on [Twitter](#), [Facebook](#), [Instagram](#), [LinkedIn](#) and [YouTube](#).

## **About Fuji Pharma**

Fuji Pharma Co., Ltd. is a Tokyo Stock Exchange (TSE) listed, Japan - based pharmaceutical company mainly engaged in the manufacture and sale of prescription based pharmaceutical products. Since our establishment in 1965, Fuji has promoted corporate philosophy that "We help people lead healthy lives by offering excellent pharmaceuticals." and "Our corporate growth is proportional to our personal growth." Fuji Pharma has focused on the field of women's health care with a wide variety of new and generic drugs for women's specific diseases such as infertility, dysmenorrhea, endometriosis, contraception, and menopausal disorders. Fuji Pharma aims to be a leading company in women's healthcare and support health of women of all ages.

<https://www.fujipharma.jp/>